AJM Pharma (Pvt.) Limited
Manufacturer & importer Has products under both a manufacturing licence (DML) and a sale licence (DSL). Source: DRAP.
Private pharmaceutical company · Karachi · Pakistan
Karachi-based pharmaceutical company focused on specialty areas including oncology, thalassaemia, nephrology and gynaecology.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- A.J. Mirza Pharma (Pvt.) Ltd.
- Company type
- Private pharmaceutical company
- Address
- 1st Floor, Shafi Court, Merewether Road, Civil Lines, Karachi, Pakistan
- Website
- ajmpharma.com ↗
- Phone
- +92 21 111 565 565
- info@ajmpharma.com
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| ABIRONE | Abiraterone acetate | 250 mg | Tablet | 120's | 114238 | PKR 177,797.01 | PKR 1,481.64/tablet | 12% below median |
| Amlotensin | Amlodipine | 5 mg | Tablet | 2x10's | 114741 | PKR 216.86 | PKR 10.84/tablet | Near median |
| Amlotensin | Amlodipine | 10 mg | Tablet | 2x10's | 114742 | PKR 299.47 | PKR 14.97/tablet | 16% below median |
| ARMOTRAZ | Anastrozole | 1 mg | Tablet | 10's | 047600 | PKR 3,273.77 | PKR 327.38/tablet | Near median |
| Artetron 20 | Artemether + Lumefantrine | 20 mg + 120 mg | Tablet | 16's | 114738 | PKR 660.90 | PKR 41.31/tablet | 5% above median |
| Artetron-DS | Artemether + Lumefantrine | 40 mg + 240 mg | Tablet | 10's | 114739 | PKR 640.24 | PKR 64.02/tablet | Near median |
| Artetron-QS 80 | Artemether + Lumefantrine | 80 mg + 480 mg | Tablet | 16's | 114740 | PKR 1,294.95 | PKR 80.93/tablet | 26% below median |
| Atenodoc | Atenolol | 50 mg | Tablet | 2x10's | 114729 | PKR 152.83 | PKR 7.64/tablet | 6% above median |
| Atenodoc | Atenolol | 100 mg | Tablet | 2x10's | 114730 | PKR 206.53 | PKR 10.33/tablet | Near median |
| Athicin | Azithromycin | 250 mg | Tablet | 6's | 114733 | PKR 309.80 | PKR 51.63/tablet | 10% above median |
| Athicin | Azithromycin | 500 mg | Tablet | 6's | 114734 | PKR 567.96 | PKR 94.66/tablet | 12% above median |
| BLEOCIP | Bleomycin | 15 IU/5 mL | Injection | 1's | 045602 | PKR 1,644.54 | PKR 1,644.54/vial/unit | No comparator |
| BLES | Bovine lipid extract surfactant (phospholipid) | 27 mg phospholipid/mL | Suspension for intratracheal administration | 1's(4ml) Vial | 087486 | PKR 28,306.60 | — | No comparator |
| BLES | Bovine lipid extract surfactant (phospholipid) | 27 mg phospholipid/mL | Suspension for intratracheal administration | 1's(3ml) Vial | 090640 | PKR 21,841.87 | — | No comparator |
| BLES | Bovine lipid extract surfactant (phospholipid) | 27 mg phospholipid/mL | Suspension for intratracheal administration | 1's(5ml) Vial | 090641 | PKR 36,403.12 | — | No comparator |
| BORTESOH | Bortezomib | 3.5 mg | Powder for injection | 1's | 114209 | PKR 55,096.75 | PKR 55,096.75/vial/unit | 48% above median |
| CALUTIDE | Bicalutamide | 50 mg | Tablet | 10's | 045650 | PKR 2,729.55 | PKR 272.96/tablet | 24% above median |
| CAPEGARD | Capecitabine | 500 mg | Tablet | 10's | 072593 | PKR 3,923.24 | PKR 392.32/tablet | 13% above median |
| Caspogin | Caspofungin | 50 mg | Powder for concentrate for infusion | 1's | 106828 | PKR 31,487.24 | PKR 31,487.24/vial/unit | Near median |
| Caspogin | Caspofungin | 70 mg | Powder for concentrate for infusion | 1's | 106829 | PKR 31,487.24 | PKR 31,487.24/vial/unit | No comparator |
| Ciprosteer | Ciprofloxacin | 250 mg | Tablet | 10's | 114765 | PKR 268.49 | PKR 26.85/tablet | 5% above median |
| Ciprosteer | Ciprofloxacin | 500 mg | Tablet | 10's | 114766 | PKR 415.69 | PKR 41.57/tablet | Near median |
| Convidecia | COVID-19 vaccine (recombinant adenovirus type 5 vector) | ≥5.0 × 10^10 viral particles/0.5 mL | Injection | 01 Dose (PFS) | 107885 | PKR 5,687.56 | PKR 5,687.56/dose | Near median |
| Convidecia | COVID-19 vaccine (recombinant adenovirus type 5 vector) | ≥5.0 × 10^10 viral particles/0.5 mL | Injection | 01 Dose (Vial) | 107886 | PKR 5,687.56 | PKR 5,687.56/dose | Near median |
| Convidecia | COVID-19 vaccine (recombinant adenovirus type 5 vector) | >5×10^10 VP/0.5 mL | Injection | 3 Doses | 107927 | PKR 16,380.18 | PKR 5,460.06/dose | No comparator |
| Corovert | Atorvastatin | 20 mg | Tablet | 10's | 115788 | PKR 454.37 | PKR 45.44/tablet | 6% below median |
| Corovert | Atorvastatin | 10 mg | Tablet | 10's | 115789 | PKR 268.49 | PKR 26.85/tablet | Near median |
| CYTOBLASTIN | Vinblastine | 1 mg | Injection | 1's | 045653 | PKR 624.92 | PKR 624.92/vial/unit | No comparator |
| Cytocarb | Carboplatin | 150 mg/15 mL | Injection | 1's | 045611 | PKR 2,137.90 | PKR 2,137.90/vial/unit | 49% below median |
| Cytocarb | Carboplatin | 450 mg/45 mL (10 mg/mL) | Injection | 1's | 047567 | PKR 4,933.62 | PKR 4,933.62/vial/unit | 40% below median |
| Cytocristin | Vincristine sulfate | 1 mg | Injection | 1's | 045654 | PKR 361.80 | PKR 361.80/vial/unit | No comparator |
| CYTOMID | Flutamide | 250 mg | Tablet | 60's | 087620 | PKR 6,020.39 | PKR 100.34/tablet | Near median |
| CYTOMID | Flutamide | 250 mg | Tablet | 100's | 087620 | PKR 10,033.98 | PKR 100.34/tablet | Near median |
| Cytoplatin | Cisplatin | 50 mg | Injection | 1's | 045612 | PKR 1,184.07 | PKR 1,184.07/vial/unit | 54% below median |
| Cytoplatin | Cisplatin | 10 mg/20 mL | Injection | 1's | 045613 | PKR 279.57 | PKR 279.57/vial/unit | 67% below median |
| CYTOTAM | Tamoxifen | 10 mg | Tablet | 10's | 045651 | PKR 172.58 | PKR 17.26/tablet | Near median |
| Daunotec | Daunorubicin HCl | 20 mg | Injection | 1's | 045601 | PKR 937.39 | PKR 937.39/vial/unit | 56% below median |
| DECARB | Dacarbazine | 200 mg | Injection | 1's | 052260 | PKR 888.06 | PKR 888.06/vial/unit | 13% below median |
| DECARB | Dacarbazine | 500 mg | Injection | 1's | 079237 | PKR 2,598.37 | PKR 2,598.37/vial/unit | No comparator |
| DOCETAX | Docetaxel | 120 mg | Injection | 1's | 066111 | PKR 60,025.73 | PKR 60,025.73/vial/unit | No comparator |
| DOLUTEGRAVIR | Dolutegravir | 50 mg | Tablet | 30's | 110538 | PKR 13,461.69 | PKR 448.72/tablet | 60% below median |
| DUOVIR + | Lamivudine + Zidovudine | 150 mg + 300 mg | Tablet | 60's | 045658 | PKR 5,811.81 | PKR 96.86/tablet | 7% below median |
| EFAVIR | Efavirenz | 600 mg | Tablet | 30's | 045663 | PKR 9,867.24 | PKR 328.91/tablet | Near median |
| EMESET | Ondansetron | 8 mg | Tablet | 10's | 081281 | PKR 1,513.31 | PKR 151.33/tablet | 9% below median |
| EPIAO | Erythropoietin | 2,000 IU/mL | Injection | 1's | 047578 | PKR 1,900.13 | PKR 1,900.13/vial/unit | No comparator |
| EPIAO | Erythropoietin | 4,000 IU/mL | Injection | 1's | 047579 | PKR 3,166.90 | PKR 3,166.90/vial/unit | No comparator |
| EPIAO | Erythropoietin | 10,000 IU/mL | Injection | 1's | 047580 | PKR 7,897.56 | PKR 7,897.56/vial/unit | No comparator |
| EPIAO | Erythropoietin | 2,000 IU/mL | Prefilled syringe injection | 1's | 092405 | PKR 1,947.64 | PKR 1,947.64/syringe | 9% below median |
| EPIAO | Erythropoietin | 4,000 IU/mL | Prefilled syringe injection | 1's | 092406 | PKR 3,710.83 | PKR 3,710.83/syringe | No comparator |
| EPIAO | Erythropoietin | 10,000 IU/mL | Prefilled syringe injection | 1's | 092407 | PKR 7,897.56 | PKR 7,897.56/syringe | Near median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.